BrainStorm Cell Therapeutics Inc (BCLI)

[Fmello]

From Zacks:

The FDA’s decision to grant an AdCom for NurOwn is indicative of the agency’s flexibility regarding therapies for terminal illnesses such as ALS, particularly when there are so few treatment options available to patients. We have the utmost confidence in BrainStorm’s management team as they prepare to present their case for NurOwn’s approval.

In addition, it’s encouraging to see that KOL’s such as Dr. Heiman-Patterson support the idea that the floor effect can influence outcomes in ALS trials, something that will undoubtedly be discussed during the AdCom.

We anticipate the announcement of the AdCom and PDUFA dates sometime in the near future. Our valuation remains at $20 per share.